Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.

Next Previous
X
Search
Trial Profile

Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clofarabine (Primary)
  • Indications B-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 28 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Planned end date changed from Oct 2009 to Oct 2010 as reported by ClinicalTrials.gov.
    • 14 Nov 2007 Expected recruitment has been reduced to 21 from 40 participants.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top